Comparison between Adisoft Technologies IPO and Goldline Pharmaceutical IPO.
Adisoft Technologies IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Goldline Pharmaceutical IPO is a SME Bookbuilding proposed to list at BSE SME.
| Adisoft Technologies IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | BSE SME |
| Lead Managers | Hem Securities Ltd. | Cumulative Capital Pvt.Ltd. |
| Registrar | Kfin Technologies Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Hem Finlease Pvt.Ltd. | Nirman Share Brokers Pvt.Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | Anchor Investor |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Adisoft Technologies IPO is up to ₹70.38 Cr whereas the issue size of the Goldline Pharmaceutical IPO is up to ₹11.02 Cr. The final issue price of Adisoft Technologies IPO is ₹172.00 per share and of Goldline Pharmaceutical IPO is ₹43.00 per share.
| Adisoft Technologies IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹163.00 per share | ₹41.00 per share |
| Issue Price (Upper) | ₹172.00 per share | ₹43.00 per share |
| Issue Price (Final) | ₹172.00 per share | ₹43.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 800 shares | 3000 shares |
| Fresh Issue Size | 40,92,000 shares | 25,62,000 shares |
| Fresh Issue Size (Amount) | up to ₹70.38 Cr | up to ₹11.02 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 40,92,000 shares | 25,62,000 shares |
| Issue Size Total (Amount) | up to ₹70.38 Cr | up to ₹11.02 Cr |
Adisoft Technologies IPO opens on Apr 23, 2026, while Goldline Pharmaceutical IPO opens on May 12, 2026. The closing date of Adisoft Technologies IPO and Goldline Pharmaceutical IPO is Apr 27, 2026, and May 14, 2026, respectively.
| Adisoft Technologies IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Anchor Bid Date | Apr 22, 2026 | May 11, 2026 |
| Issue Open | Apr 23, 2026 | May 12, 2026 |
| Issue Close | Apr 27, 2026 | May 14, 2026 |
| Basis Of Allotment (Tentative) | Apr 28, 2026 | May 15, 2026 |
| Initiation of Refunds (Tentative) | Apr 29, 2026 | May 18, 2026 |
| Credit of Share (Tentative) | Apr 29, 2026 | May 18, 2026 |
| Listing date (Tentative) | Apr 30, 2026 | May 19, 2026 |
| Anchor Lockin End date 1 | May 28, 2026 | Jun 14, 2026 |
| Anchor Lockin End date 2 | Jul 27, 2026 | Aug 13, 2026 |
Adisoft Technologies IPO P/E ratio is 12.82, as compared to Goldline Pharmaceutical IPO P/E ratio of 10.47.
| Adisoft Technologies IPO | Goldline Pharmaceutical IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 99.98 | 79.70 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 73.6 | 57.29 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 12.82 | 10.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹280.67 Cr. | ₹41.28 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 39.11 | 35.83 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 29.12 | 38.45 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.58 | 1.50 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹13.41 | ₹4.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 32.71 | 27.37 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Adisoft Technologies IPO Retail Individual Investors (RII) are offered 14,33,600 shares while in Goldline Pharmaceutical IPO retail investors are offered 14,33,600 shares. Qualified Institutional Buyers (QIB) are offered 8,18,400 shares in Adisoft Technologies IPO and 5,40,000 shares in Goldline Pharmaceutical IPO.
| Adisoft Technologies IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Anchor Investor Reservation | 12,25,600 shares | 7,32,000 shares |
| Market Maker Reservation | 2,16,000 shares | 1,38,000 shares |
| QIB | 8,18,400 shares | 5,40,000 shares |
| NII | 6,14,400 shares | 3,90,000 shares |
| RII | 14,33,600 shares | 9,00,000 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 40,92,000 shares | 25,62,000 shares |
Adisoft Technologies IPO subscribed 54.25x in total, whereas Goldline Pharmaceutical IPO subscribed 600.53x.
| Adisoft Technologies IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| QIB (times) | 98.23x | 180.22x |
| NII (times) | 120.16x | 1,662.04x |
| Big NII (times) | 149.66x | 2,010.60x |
| Small NII (times) | 61.16x | 980.75x |
| RII (times) | 47.27x | 881.15x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 54.25x | 600.53x |
